Navigation Links
Common Drug Eases Restless Legs Syndrome
Date:4/29/2009

Lyrica also improves quality of sleep for patients, study finds,,,,

WEDNESDAY, April 29 (HealthDay News) -- Lyrica, a drug used to treat epilepsy, nerve pain, anxiety and fibromyalgia, shows promise in easing the symptoms of restless legs syndrome, a Spanish researcher reports.

Some 5 percent to 10 percent of adults in the United States have restless legs syndrome (RLS), a disorder that causes people to feel a compelling need to move their legs, especially while lying down. The condition can have a substantial impact on sleep, daily activities and quality of life, researchers say.

"This is the first time this drug is being tried for RLS," said Dr. Diego Garcia-Borreguero, director of the Sleep Research Institute in Madrid. "Pregabalin [Lyrica] is an effective drug for the treatment of RLS -- it leads about 60 percent of patients into clinical remission."

The drug improves both the sensation and motor symptoms of RLS, Garcia-Borreguero said.

He also noted that patients taking Lyrica had improved quality of sleep. "Other drugs for RLS had not been able to solve this problem," he said. "They have not been able to improve sleep."

This use of Lyrica is an off-label one, Garcia-Borreguero cautioned.

The findings were to be presented Wednesday at the American Academy of Neurology's annual meeting, in Seattle.

For the study, Garcia-Borreguero randomly assigned 58 people with RLS to Lyrica or a placebo. Sleep studies were performed at the beginning and end of the 12-week trial.

Garcia-Borreguero found that almost 75 percent of patients taking Lyrica had RLS symptoms stop while taking the drug. Among those who continued to have RLS, their symptoms improved by 66 percent. Patients on placebo saw their symptoms worsen by 29 percent.

In addition, those taking Lyrica had better sleep compared with patients taking placebo. Patients on Lyrica had more slow-wave sleep, or deep sleep. They also spent less time in the lighter sleep stages compared with people taking placebo, Garcia-Borreguero said.

RLS presents as an urge to move the legs, often with unpleasant numbness, tingling or burning sensations. These symptoms increase during rest and are partially relieved through activity. Symptoms worsen at night and tend to progress with age.

The study was funded by Pfizer Inc., the maker of Lyrica.

Dr. Carlos Singer, director of the Movement Disorders Center at the University of Miami School of Medicine, thinks Lyrica provides an alternative to other drugs for RLS and may also have fewer side effects.

"You have another weapon to treat RLS," Singer said. "This drug, to the best of my knowledge, has a very safe record," he said. "I would definitely try it with patients."

Singer noted that more studies are needed to see if the drug is still effective for RLS after long-term use.

More information

For more information on restless legs syndrome, visit the U.S. National Institute of Neurological Disorders and Stroke.



SOURCES: Diego Garcia-Borreguero, M.D., director, Sleep Research Institute, Madrid, Spain; Carlos Singer, M.D., professor, neurology, and director, Movement Disorders Center, University of Miami School of Medicine; April 29, 2009, presentation, American Academy of Neurology's annual meeting, Seattle


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Penn Medicine, CHOP researchers demonstrate first common genetic risk factors for autism
2. Mental health problems more common in kids who feel racial discrimination
3. Type of vitamin B1 could treat common cause of blindness
4. Commonly used ulcer drugs may offer treatment potential in Alzheimers disease
5. The Most Common Cause of Hair Loss Is the Least Suspected, Warns Trichology Expert
6. Canadian Medical Device Set to Speed Treatment and Cut Health Care Costs for Common Cause of Vertigo
7. Silent Heart Attacks More Common Than Thought
8. Mayo Clinic-led researchers confirm gene variants associated with the most common adult leukemia
9. All Persons Who Purchased or Acquired the Common Stock of Sunrise Senior Living, Inc. (Sunrise) Between February 26, 2004 and July 28, 2006, Inclusive, and Were Damaged Thereby (The Class)
10. Tianyin Pharmaceutical Co., Inc. Series A Preferred Shareholders Approved Cash Dividend to Common Stockholders
11. Common Industrial Chemicals May Not Boost Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Common Drug Eases Restless Legs Syndrome
(Date:6/26/2016)... ... , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... a whole new perspective by using the title layers in ProSlice Levels to ... ProSlice Levels contains over 30 Different presets to choose from. FCPX users ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
Breaking Medicine Technology: